TECH Signal 198
In mice, Ozempic activates hunger neurons that are essential for sustaining fat loss
↗
A Yale study in mice found that semaglutide (Ozempic) activates AgRP hunger neurons, and these neurons are required for the drug to sustain weight loss, overturning the assumption that they work against it.
The finding challenges the long-held assumption that GLP-1 drugs work by suppressing hunger neurons. It suggests that the brain's hunger circuitry is actively recruited to maintain fat loss, which could point to new targets for more effective obesity drugs. However, the experiments were in mice, so human relevance is not yet confirmed.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
Yale researchers found that semaglutide activates AgRP hunger neurons in mice, not suppresses them.
Mice lacking AgRP neurons could not sustain weight loss on GLP-1 drugs, showing these neurons are required.
The study, published in PNAS, suggests a new mechanism for GLP-1 therapies and potential targets for better obesity drugs.
THE CLUSTER